Buying Groups Can Help, but Clinics Still Need a Broader Vendor-Cost Strategy
Program access creates leverage. Clinic-specific analysis determines the true economic and operational result.
Brian Fosselman, Founder, Cura Veterinary PartnersJuly 28, 202611 min read
Recurring vendor expenses deserve the same structured attention that independent veterinary clinics give to staffing, pricing, workflow, client experience, and growth. For clinics that already belong to a buying group or group purchasing organization, that recommendation can prompt a reasonable question: Have we already addressed our vendor costs?
Buying groups can provide meaningful advantages. They may give an independent clinic access to negotiated pricing, manufacturer and distributor programs, rebates, and aggregated purchasing leverage that the clinic could not obtain on its own. They can also reduce the time required to identify certain purchasing programs and maintain commercial relationships across a complex supplier market.
Participation alone does not establish whether those benefits are fully reaching the clinic's bottom line. The answer depends on which purchases qualify, how the clinic buys in practice, whether expected rebates are earned and received, what additional costs apply, and how much of the clinic's broader vendor portfolio the program addresses.
A buying group can be a valuable part of the clinic's purchasing strategy. A complete vendor-cost strategy determines how well that part is working, where other purchasing routes may be useful, and which recurring expenses still deserve attention.
What clinic owners should know
Buying groups can provide substantial value. Aggregated purchasing leverage, preferred pricing, rebates, and supplier programs can improve the economics available to independent veterinary practices.
Access and realized value are different measures. Product eligibility, purchasing volume, staff utilization, rebate requirements, fees, freight, and order minimums can affect how much of the advertised benefit reaches the clinic.
The veterinary purchasing landscape contains many possible routes. Buying groups, cooperatives, association programs, distributors, manufacturer-direct agreements, purchasing platforms, incumbent negotiations, and hybrid arrangements may overlap.
The strongest purchasing route may differ by category. A buying-group program may be the best choice for one category, while a distributor, manufacturer-direct relationship, negotiated incumbent agreement, or competitive alternative may produce a better result elsewhere.
A sound review can validate existing arrangements. The appropriate conclusion may be to maintain the current buying group or vendor when the economics, service, and operational fit are already strong.
Industry context: Participation is common, but visibility into results varies
80%
of responding veterinary managers said their practices belonged to a GPO.
About one-third
did not know how much their practices saved annually through GPO membership.
More than 40%
either did not know whether their GPO generally provided the best pricing or believed that advantage applied only to limited products.
These findings come from a September 2020 Veterinary Hospital Managers Association survey. They indicate that GPO participation was common among the managers surveyed, while visibility into realized savings and category-level pricing remained less consistent. The percentages describe survey respondents and should not be interpreted as a current adoption estimate for all U.S. veterinary practices.
Buying groups help address an important scale disadvantage
Independent clinics generally purchase at a smaller scale than large veterinary networks. A buying group can aggregate the purchasing activity of many practices and use that combined volume to negotiate commercial programs with manufacturers, distributors, and other suppliers.
Depending on the organization, participating clinics may gain access to preferred item-level pricing, growth rebates, purchase credits, manufacturer promotions, distributor arrangements, or business resources. Some groups also track available programs, manage supplier relationships, and help practices identify opportunities that would otherwise require considerable time to investigate.
These benefits can be particularly meaningful in pharmaceuticals, preventives, vaccines, medical supplies, prescription diets, and other cost-of-goods-sold categories. When a clinic spends substantially and consistently within a qualifying category, even a modest improvement in effective cost can support cash flow and operating flexibility.
Buying groups therefore have an important role in the independent veterinary market. For many clinics, continued membership will remain a sound decision.
The broader analysis begins with a different question: How effectively does the clinic convert its available program access into measurable economic value?
The purchasing landscape is broader than a single membership decision
Buying-group membership represents one choice within a much larger veterinary purchasing market. Independent clinics may encounter standalone GPOs, member-owned cooperatives, association-sponsored programs, management or peer organizations with purchasing components, specialty-focused groups, distributor programs, manufacturer-direct offers, purchasing platforms, and independently negotiated vendor agreements.
These examples do not represent a complete market census, but they demonstrate how quickly the available programs and supplier relationships can multiply. Each underlying arrangement can carry its own eligible products, volume requirements, purchasing channels, rebate structures, contract terms, and administrative processes. Program availability may also depend on practice type, geography, membership eligibility, purchasing volume, or supplier relationships.
This breadth gives independent clinics more ways to improve their purchasing economics. It also makes comparison difficult. Practice leaders must determine which options are available, which purchases qualify, which arrangements the team will use consistently, and which combination provides the strongest balance of true net cost, service, flexibility, and operational fit.
The relevant question therefore extends beyond whether a clinic belongs to a buying group. Practice leaders need to understand whether they have evaluated the appropriate options and assembled the right purchasing structure for their clinic.
Exhibit 1
The Complete Vendor-Cost Strategy
Buying groups can provide valuable program access. Economic evaluation, clinic-specific decisions, implementation, and verification determine the final result.
LEVEL 1Many Purchasing Routes
Group-Based Programs
Standalone GPO
Member-owned cooperative
Association or specialty program
Distributor Programs
Primary or secondary distributor
Private-label options
Volume or growth programs
Manufacturer Direct
Portfolio programs
Volume tiers
Rebates and credits
Independent Vendor Relationships
Existing incumbent
Category specialist
Competitive alternative
Purchasing Platforms and Hybrid Models
Multi-supplier platform
Program-tracking platform
Combined group and direct purchasing
Each route may contain multiple programs, vendors, and commercial structures.
LEVEL 2Economic Evaluation
Qualifying Spend
True Net Cost
Discounts and Rebates
Fees and Freight
Contract Terms
Service Requirements
Administrative Effort
LEVEL 3Strategic Decision
Maintain the Current Arrangement
Improve the Existing Agreement
Adjust Program Participation
Use Different Routes by Category
Evaluate Competitive Alternatives
LEVEL 4Implementation and Verification
Contract Execution
Purchasing Alignment
Team Communication
Operational Transition
Savings Verification
Source: Cura Veterinary Partners.
Program access does not guarantee full program utilization
A clinic may qualify for preferred pricing while continuing to purchase some products through another channel. Doctors may use products outside the preferred portfolio because of clinical preferences or patient needs. Inventory responsibilities may be distributed among several employees, each with different ordering habits.
These decisions may be entirely appropriate, but they affect the portion of annual spend that receives the expected program benefit. Applying an advertised discount to the clinic's total category spend can therefore produce an inaccurate savings estimate.
Volume thresholds and product-mix requirements create another layer of complexity. Some benefits depend on purchasing a minimum amount, maintaining compliance across a product family, or reaching a defined growth target during a measurement period. A clinic that falls slightly below the requirement may realize considerably less value than the maximum program opportunity suggests.
Rebates can be difficult to evaluate without a disciplined reconciliation process. Payments or credits may arrive after the original purchase, appear across multiple statements, or depend on information submitted by a distributor or manufacturer.
For example, AAHA's current purchasing-program materials state that savings vary with purchasing volume and that the program's annual fee is deducted from rebates. These terms are specific to that program, but they illustrate why volume, qualification, program costs, and reconciliation influence realized value.
Practice leaders may know that the clinic participates in a rebate program without being able to confirm whether the expected amount was earned and received. A complete review connects program terms with actual purchasing data and financial records.
The strongest purchasing route may differ by category
No single purchasing route is inherently best across every category. A buying group may provide the strongest pricing and program support for one manufacturer, while a distributor may offer better logistics and product breadth for general supplies. A manufacturer-direct relationship may be more attractive when a clinic has concentrated volume in a particular product family.
Existing vendors also deserve consideration. An incumbent supplier may be willing to improve pricing, revise contract terms, or address service issues when presented with a credible market comparison. Retaining the incumbent can preserve continuity and reduce implementation demands.
Competitive alternatives become relevant when the current arrangement no longer provides a satisfactory combination of economics, service, flexibility, and operational fit. A lower quoted price should still be evaluated against contractual commitments, transition requirements, staff workload, and the risk of disrupting a category that supports daily clinical operations.
The clinic may ultimately use several purchasing routes at the same time. That outcome often reflects a disciplined category-by-category strategy rather than an inconsistent purchasing model.
Exhibit 2
Which Purchasing Route Is Best?
Decision inputs
True Net Cost
Eligible Purchasing Volume
Clinical and Service Requirements
Contract Terms
Administrative Effort
Implementation Complexity
Clinic-specific evaluation
Which route produces the strongest overall result for this category?
Potential routes
Buying Group / GPO
Multiple possible groups and programs
Distributor
Multiple possible suppliers and arrangements
Manufacturer Direct
Multiple possible portfolios and volume structures
Negotiated Incumbent
Potential improvements to the current relationship
Competitive Alternative
Multiple possible category-specific vendors
Decision inputs
True Net Cost
Eligible Purchasing Volume
Clinical and Service Requirements
Contract Terms
Administrative Effort
Implementation Complexity
↓
Clinic-specific evaluation
Which route produces the strongest overall result for this category?
↓
Potential routes
Buying Group / GPO
Multiple possible groups and programs
Distributor
Multiple possible suppliers and arrangements
Manufacturer Direct
Multiple possible portfolios and volume structures
Negotiated Incumbent
Potential improvements to the current relationship
Competitive Alternative
Multiple possible category-specific vendors
The appropriate result may use several routes across different categories.
Source: Cura Veterinary Partners.
The quoted discount is only one part of the economics
A quoted price or advertised discount provides a useful starting point. It does not capture every component of the clinic's financial result.
The analysis should first determine how much of the clinic's historical spend qualifies. It should then account for the rebates and credits the clinic can reasonably expect to earn, rather than applying the maximum advertised percentage without considering volume or product-mix requirements.
Fees, freight, minimum-order rules, and service charges may offset part of the benefit. Payment terms and rebate timing can also affect cash flow, especially when the clinic pays for products well before receiving the associated credit.
Operational costs belong in the comparison as well. Changing distributors, altering formularies, updating inventory procedures, training employees, or migrating to a new ordering platform can consume team capacity. A small price advantage may not justify the disruption. A larger, sustainable improvement may warrant the effort when the implementation plan protects service continuity and clinical needs.
The relevant measure is true net cost, considered alongside service quality, reliability, contractual flexibility, clinical fit, and team workload.
Exhibit 3
From Quoted Price to True Net Cost
Quoted Price
Contractual Discounts
Earned Rebates and Credits
Program or Membership Fees
Freight, Service Charges, and Minimum-Order Effects
Implementation and Operational Costs
True Net Cost
Quoted Price
↓
−Contractual Discounts
↓
−Earned Rebates and Credits
↑
+Program or Membership Fees
↑
+Freight, Service Charges, and Minimum-Order Effects
↑
+Implementation and Operational Costs
=
True Net Cost
Consider alongside
Service QualityReliabilityContract FlexibilityClinical FitTeam Workload
Illustrative framework; adjustment sizes are not to scale.
Expected rebates should reflect the amount the clinic can reasonably qualify for and receive, rather than the maximum advertised opportunity.
Source: Cura Veterinary Partners.
A complete strategy extends beyond cost-of-goods-sold categories
Buying-group offerings vary considerably. Some programs cover a broad range of manufacturers, distributors, products, and services. Others concentrate on defined supplier relationships or purchasing categories.
Their influence is often most visible in cost-of-goods-sold categories such as pharmaceuticals, preventives, vaccines, medical supplies, and prescription diets. Those categories can represent substantial annual spend and deserve careful analysis.
Independent clinics also incur recurring expenses across a much wider vendor portfolio. Many of those costs involve separate contracts, pricing structures, service models, and renewal processes. Participation in a strong product-purchasing program does not establish whether those operating categories are competitive.
Category view
Where buying-group coverage may end
Often addressed through buying-group programs
Medical SuppliesPharmaceuticalsPreventives and VaccinesPrescription DietsSelected DiagnosticsOther Qualifying Purchases
Frequently requiring separate review
Payment ProcessingInsurance and Employee BenefitsPhone and CommunicationsDigital MarketingSoftware and SubscriptionsWaste and Regulated WasteCremation and AftercarePayroll and Administrative ServicesCertain Reference Laboratory ArrangementsCertain Teleradiology ArrangementsOther Recurring Services
Note: Program coverage varies by organization, vendor, and practice.
What a clinic-specific review should answer
A productive review should move through three distinct stages.
01|Coverage and utilization
The clinic should identify which categories, vendors, products, and purchasing channels are included in its current programs. Historical purchasing data can then show how much annual spend qualifies and how much flows through the preferred arrangements in practice.
This stage should also examine whether clinical preferences, inventory processes, or ordering habits explain any gap between available benefits and actual utilization. The objective is to understand the current state accurately before estimating an opportunity.
02|Economics and contractual terms
The clinic should calculate true net cost after discounts, rebates, credits, fees, freight, and minimum-order requirements. Expected program benefits should be reconciled with amounts actually received wherever the data permit.
Pricing must be considered together with contract length, renewal provisions, notice deadlines, service commitments, payment terms, and any exclusivity requirements. An economically attractive arrangement can become less valuable when the contract limits flexibility or the service model does not meet the clinic's needs.
03|Alternatives and implementation
The clinic should determine whether a buying-group program, distributor, manufacturer-direct agreement, negotiated incumbent arrangement, or competitive alternative provides the strongest overall result. The comparison should reflect the clinic's expected purchasing volume and service requirements rather than a generic market assumption.
Any proposed change should then be evaluated against implementation effort, clinical continuity, team capacity, and operational risk. Savings that cannot be implemented effectively have limited practical value.
An illustrative clinic example
Consider an independent clinic that belongs to a buying group and receives preferred pricing and rebates within a major product category. Clinic leadership reasonably believes the category has already been addressed.
A review of the clinic's purchasing history shows that a significant portion of its spend qualifies for the program, but several high-volume products fall outside the preferred portfolio. Some purchases are also being made through a different channel, and the clinic cannot fully reconcile the expected rebates with the credits it has received. Freight and minimum-order requirements reduce part of the anticipated benefit.
A comparison of the available routes produces a mixed conclusion. A manufacturer-direct arrangement offers better true net economics for one concentrated group of products. The existing buying-group program remains the strongest option for the balance of the category because it provides competitive pricing, convenient ordering, and reliable service.
The review also identifies an opportunity in a recurring operating category that the buying group does not cover.
The clinic keeps its buying-group membership, modifies one purchasing relationship, and evaluates a separate operating expense. Each decision reflects the economics and operational requirements of the category involved.
That is the purpose of a complete vendor-cost strategy: to determine where current arrangements are working, where they can be improved, and where another approach may create greater value.
Where Cura Veterinary Partners fits
Cura Veterinary Partners helps independent veterinary clinics evaluate the full vendor picture. The work begins by establishing an accurate spend baseline and understanding the clinic's existing suppliers, purchasing channels, contracts, service requirements, and operational constraints.
01|Establish the baseline
Cura reviews relevant invoices, purchasing records, contracts, fee structures, and renewal terms. The objective is to establish how much the clinic spends, which arrangements apply, and what financial benefits the clinic is currently receiving.
02|Evaluate the options
Cura can compare buying-group, distributor, manufacturer-direct, incumbent, and independent vendor options using consistent economic assumptions. The analysis considers realized discounts and rebates, contract terms, service quality, implementation requirements, and the expected effect on clinic operations.
Where a market check or structured competitive process is appropriate, Cura can support the evaluation of alternatives and negotiations with existing or prospective vendors.
03|Execute and verify
When the clinic selects a course of action, Cura can assist with implementation and verify the documented financial result. Expected savings are evaluated against the work required to achieve them, with appropriate attention to clinical continuity and team capacity.
The process does not begin with an assumption that the clinic should leave its buying group, replace an incumbent, or choose the lowest nominal price. Existing arrangements may already provide the best combination of economics, quality, service, and operational fit.
A clinic-specific review can therefore reach several valid conclusions:
Keep the existing arrangement
The current buying-group program or vendor already provides strong economics and reliable service.
Improve the current arrangement
Pricing, rebates, contract terms, purchasing compliance, or administrative processes can be strengthened without changing vendors.
Use a different route for a defined category
A direct, distributor, incumbent, or competitive arrangement produces a better overall result for a specific portion of spend.
The objective is to identify the combination of programs, channels, vendors, and terms that works best for the clinic.
Cura's perspective
Buying groups can provide independent veterinary clinics with meaningful purchasing leverage, preferred programs, and access to supplier relationships. Their value should be recognized, measured, and used where the economics and clinical requirements align.
The veterinary purchasing market also contains many organizations, programs, products, channels, and overlapping commercial arrangements. Clinic leaders may have access to more options than they realize, while still lacking a practical way to compare those options against their actual purchasing data.
The clinic's final result depends on purchasing behavior, qualifying volume, realized rebates, additional costs, contract terms, service performance, and implementation demands. Categories outside the program require their own evaluation.
Access to a buying group can create leverage. A complete vendor-cost strategy determines where that leverage is working, where it is not, and what other opportunities deserve attention.
The strongest outcome may involve keeping the current program in one category, improving an incumbent agreement in another, and evaluating a competitive alternative elsewhere. That approach supports better economics while protecting clinical quality, service continuity, and team capacity.
Could a structured vendor review create meaningful value for your clinic?
If your clinic already uses a buying group but still wonders whether its vendor costs are fully optimized, book a 15-minute introductory call with Cura Veterinary Partners.
Brian Fosselman is the founder of Cura Veterinary Partners. His background includes management consulting work focused on procurement-related cost optimization, strategic negotiations, and business performance improvement. Through Cura, he helps independent veterinary clinics evaluate vendor spend, negotiate stronger agreements, and improve cash flow while limiting additional demands on clinical teams.